ChemGenex raises $12.9m
Wednesday, 17 September, 2008
ChemGenex [ASX: CXS] has completed a $12.9 million capital raising through a share placement to institutional investors.
15.2 million shares were sold at $0.85 per share. Over half of these shares were purchased by existing major ChemGenex shareholders.
The company is also offering existing Australian shareholders the ability to participate on the same terms.
Existing major shareholders Alta Partners, GBS Venture Partners and Merck Snate committed $6.5 million.
The funds will be used for ChemGenex’s clinical trial program of its lead drug candidate, omacetaxine, for chronic myeloid leukaemia.
NSW Govt delivers foot-and-mouth vaccine to protect livestock
A biodegradable vaccine to protect livestock from foot-and-mouth disease has been developed as...
Scientists optimise delivery of mRNA to target cells
A highly versatile new method captures and attaches antibodies to the surface of mRNA-loaded...
'Anti-reward' brain network helps explain cocaine addiction
A new study identifies a specific 'anti-reward' network deep in the brain that undergoes...
